Chemical and Pharmaceutical Bulletin · 2019 · 23 citations · 7 references
PharmacyChemistryPharmacologyCrystal StructureDrug DesignPharmaceutical FormulationCrystal ChemistryCrystallization ProcessesDrug SolubilityPharmaceutical StabilitySolubility EnhancementSolubility OptimizationAqueous Solubility ImprovementCo-crystal FormationCocrystal FormationCrystallizationLow SolubilityPharmaceutical CocrystallizationPowder X-ray DiffractionSolubility
In this present study a new co-crystals of zoledronic acid with DL-tartaric acid and nicotinamide has been developed with improved solubility. Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and low aqueous solubility; hence an attempt has been made to improve its solubility by co-crystallization technology. Pharmaceutical cocrystals are multi-component crystals with a stoichiometric ratio of active pharmaceutical ingredients (APIs) and cocrystal coformers (CCFs) that are assembled by noncovalent interactions such as hydrogen bonds, π-π packing, and Vander Waals forces. In this study the coformers selected were DL-tartaric acid and nicotinamide based on ease of hydrogen bond formation. The co-crystal of zoledronic acid with DL-tartaric acid were prepared in three ratios (1 : 1, 1 : 2 and 2 : 1) by slow solvent evaporation method and with nicotinamide in 1 : 1 ratio by dry grinding method. The formation of co-crystal was confirmed by powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC) and Fourier transform (FT)IR. The dynamic solubility of co-crystals with DL-tartaric acid in the ratios 1 : 1, 1 : 2 and 2 : 1 increased by fold as compared to pure drug.
7
Pharmaceutical Cocrystals and Their Physicochemical Properties
N. Schultheiss, Ann Newman · Crystal Growth & Design · 2009 · 1.5K citations · Full text
Ok-Cheol Jeon, Dong-Hyun Seo, Han Sung Kim et al. · European Journal of Pharmaceutical Sciences · 2015 · 25 citations